At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 32 enrolled
Drug / intervention
galidesivir +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Double-blind, Placebo Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Galidesivir (BCX4430) Administered as Single Doses Via Intravenous Infusion in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating galidesivir and placebo for Marburg Virus Disease. Completed, enrolled 32 participants across 1 site.
Detailed Summary
This is a placebo-controlled, randomized, double-blind study to evaluate the pharmacokinetics of galidesivir following administration of single doses by IV infusion
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMarburg Virus Disease
CountriesUnited States
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
Enrollment StartDec 2018
First PostedJan 2019
Primary CompletionApr 2019
TodayJul 2026
First PostedJan 11, 2019
Enrollment StartDec 10, 2018
Primary CompletionApr 30, 2019
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 7.5 years ago
Interventions
galidesivirdrug
galidesivir IV infusion
placebodrug
placebo IV infusion